Malaysia
Search
Sign In
Cardiology
Top Medical News
Patients undergoing peritoneal dialysis (PD) with cardiovascular disease (CVD) show significantly higher echocardiographic calcium score (ECS) than those without CVD, according to a Singapore study. This indicates a higher vascular calcification burden in the former.
Postmortem interrogation of cardiac implantable electrical devices (CIED) can help pinpoint a patient’s time of death, according to a recent study. While forensic analysis of explanted CIEDs is valid, accuracy of time determination varies across different devices.
Following nonvalvular atrial fibrillation (NVAF)-associated stroke events, a graded increase in delay in direct oral anticoagulants (DOACs) initiation of between 1 and 4 days, depending on the severity of the index event, appears to be effective for recurrent stroke prevention and does not compromise safety both in Asians and Europeans, according to a recent study.
Intensive management of blood pressure (BP) leads to a significant reduction in cardiovascular events in overweight, obese I, and obese II patients without elevating safety risks, a study has shown.
In very elderly nonvalvular atrial fibrillation (NVAF) patients who are ineligible for standard anticoagulation, increasing levels of B-type natriuretic peptide (BNP) appear to be correlated with higher risks of stroke or systemic embolism, reports a new study.
A recent meta-analysis offers new proof of different canagliflozin doses for hypertension management in patients with type 2 diabetes mellitus (T2DM) complicated by hypertension. However, low-density lipoprotein cholesterol (LDL-C) and the risk of urinary tract infection must be observed.
Implantation with new-generation, self-expanding aortic valves appears to result in a significant spike in the rates of high-degree cardiac conduction disturbance, such as an increase in PR and QRS intervals, reports a new study.
Special Reports
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.
Heart failure with preserved
ejection fraction (HFpEF) represents a significant unmet medical need. The
EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on
cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the
hotline session of the 2021 ESC Virtual Congress, the main results of the
EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal
investigator of the study, and heart failure specialist at Charité Berlin,
Germany.
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]
Edoxaban 30 mg and 60 mg FC tab
Perindopril arginine 3.5 mg,
Amlodipine besilate 2.5 mg tab
Amlodipine besilate 2.5 mg tab
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Conference Reports
The risk of subclinical valve leaflet thrombosis (SLT) following transcatheter aortic valve replacement (TAVR) did not differ regardless of whether patients received edoxaban or dual antiplatelet therapy (DAPT) post-surgery, according to results of the ADAPT-TAVR* trial.
Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.
Among patients on concomitant treatment with direct oral anticoagulants (DOACs) and dronedarone, no difference is seen in survival free from the composite endpoint (ie, clinically relevant bleeding, thromboembolic event, and all-cause death) and from clinically relevant bleeding between groups of coadministration, according to a study.
The cardioprotective effects of exercise are nearly twice as large in people with anxiety and depression than in those without, suggests a new study presented at ACC.22.
Use of bipolar radiofrequency ablation (BRFA) is both safe and effective in selected patients who have failed at least one standard unipolar approach, suggest the results of a systematic review and meta-analysis. However, the quality of the supporting evidence is low.
When it comes to sports-related* sudden cardiac death (SCD) rates, men appear to have it worse than women, according to data presented at EHRA 2022.
Adding mavacamten – an allosteric modulator of cardiac myosin – to maximal medical therapy slashes the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (OHCM) who are candidates for such intervention, the VALOR-HCM trial has shown.
Multimedia
.png)
